Rare HPV Airway Disease Gets First DNA-Based Immunotherapy as FDA Grants Accelerated Approval to Inovio's Voceryq
The FDA granted accelerated approval to Inovio's Voceryq for adults with recurrent respiratory papillomatosis, a rare HPV-related airway disease requiring repeated surgeries.
Medical Daily ·